Atea Pharmaceuticals (AVIR) EPS (Weighted Average and Diluted) (2020 - 2026)
Atea Pharmaceuticals (AVIR) recorded quarterly EPS (Weighted Average and Diluted) of -$0.57 in Q1 2026, little changed quarter-over-quarter from -$0.57 in Q4 2025, and down 42.5% on a YoY basis from -$0.99 in Q1 2025.
Atea Pharmaceuticals (AVIR) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Atea Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$0.57 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 42.5% year-over-year to -$0.57; the TTM figure through Mar 2026 stood at -$2.11 (down 27.88% YoY), while the FY2025 annual figure was -$1.94, up 3.0% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.57 for Q1 2026 at Atea Pharmaceuticals, roughly flat from -$0.57 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.1 in Q3 2022 to a low of -$0.75 in Q1 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.44 across 5 years, with a median of -$0.43 in 2023.
- Biggest YoY gain for EPS (Weighted Average and Diluted) was 70.59% in 2022; the steepest drop was 2000.0% in 2022.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.41 in 2022, then declined by 14.63% to -$0.47 in 2023, then rose by 14.89% to -$0.4 in 2024, then slumped by 42.5% to -$0.57 in 2025, then retreated by 0.0% to -$0.57 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.57 (Q1 2026), -$0.57 (Q4 2025), and -$0.53 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | Atea Pharmaceuticals | 347.68 Mn | 347.68 Mn | - | -0.57 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.57 |
| Dec 31, 2025 | -0.57 |
| Sep 30, 2025 | -0.53 |
| Jun 30, 2025 | -0.44 |
| Mar 31, 2025 | -0.40 |
| Dec 31, 2024 | -0.40 |
| Sep 30, 2024 | -0.37 |
| Jun 30, 2024 | -0.48 |
| Mar 31, 2024 | -0.75 |
| Dec 31, 2023 | -0.47 |
| Sep 30, 2023 | -0.40 |
| Jun 30, 2023 | -0.34 |
| Mar 31, 2023 | -0.43 |
| Dec 31, 2022 | -0.41 |
| Sep 30, 2022 | -0.10 |
| Jun 30, 2022 | -0.38 |
| Mar 31, 2022 | -0.51 |
| Dec 31, 2021 | 1.32 |
| Sep 30, 2021 | -0.34 |
| Jun 30, 2021 | 0.02 |